Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2 true The principal activity of the Company is the development and provision of tools and resources to support individuals affected by autoimmune conditions.false false true 2024-06-24 15799123 2024-06-23 15799123 2024-06-24 2024-12-31 15799123 2023-06-24 2024-06-23 15799123 2024-12-31 15799123 c:Director1 2024-06-24 2024-12-31 15799123 d:CurrentFinancialInstruments 2024-12-31 15799123 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 15799123 d:ShareCapital 2024-12-31 15799123 d:SharePremium 2024-12-31 15799123 d:RetainedEarningsAccumulatedLosses 2024-12-31 15799123 c:OrdinaryShareClass1 2024-06-24 2024-12-31 15799123 c:OrdinaryShareClass1 2024-12-31 15799123 c:OrdinaryShareClass2 2024-06-24 2024-12-31 15799123 c:OrdinaryShareClass2 2024-12-31 15799123 c:FRS102 2024-06-24 2024-12-31 15799123 c:AuditExempt-NoAccountantsReport 2024-06-24 2024-12-31 15799123 c:FullAccounts 2024-06-24 2024-12-31 15799123 c:PrivateLimitedCompanyLtd 2024-06-24 2024-12-31 15799123 e:PoundSterling 2024-06-24 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15799123 OTOIMMUNE LTD UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE PERIOD ENDED 31 DECEMBER 2024
OTOIMMUNE LTD REGISTERED NUMBER: 15799123 BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024
Note |  | £
CURRENT ASSETS |  |  |
Debtors: amounts falling due within one year | 4 | 2,500 |
Cash at bank and in hand |  | 205,056 |
|  | 207,556 |
Creditors: amounts falling due within one year | 5 | (31,275) |
NET CURRENT ASSETS |  |  | 176,281
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 176,281
NET ASSETS |  |  | 176,281
CAPITAL AND RESERVES |  |  |
Called up share capital | 6 |  | 1
Share premium account |  |  | 177,505
Profit and loss account |  |  | (1,225)
|  |  | 176,281
Page 1
OTOIMMUNE LTD REGISTERED NUMBER: 15799123 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
Dr J A Mellad
Director
Date: 12 September 2025
The notes on pages 3 to 5 form part of these financial statements. Page 2
OTOIMMUNE LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
1. | GENERAL INFORMATION
OtoImmune Ltd is a private company limited by shares and incorporated in England and Wales on 24 June 2024. Its registered office is 20 Wenlock Road, London, N1 7GU. The Company's functional and presentational currency is GBP. 2.ACCOUNTING POLICIES
| 2.1 | BASIS OF PREPARATION OF FINANCIAL STATEMENTS
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | TAXATION
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
| 2.3 | DEBTORS
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment. Page 3
OTOIMMUNE LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024 2.ACCOUNTING POLICIES (CONTINUED)
| 2.4 | CASH AND CASH EQUIVALENTS
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.5 | CREDITORS
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | EMPLOYEES
| The average monthly number of employees, including directors, during the period was 2.
4. | DEBTORS
|  |  |  |  | 2024
|  |  |  |  | £
| Other debtors | 2,500
5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
|  |  |  |  | 2024
|  |  |  |  | £
| Trade creditors | 30,000
| Other creditors | 25
| Accruals and deferred income | 1,250
|  | 31,275
Page 4
OTOIMMUNE LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
6. | SHARE CAPITAL
|  |  |  |  | 2024
|  |  |  |  | £
|  | ALLOTTED, CALLED UP AND FULLY PAID |
|  | 933,332 Ordinary shares of £0.000001 each | 1
|  | 36,284 Pre-Seed shares of £0.000001 each | -
|  |  | 1
On incorporation, the Company issued 700,000 £0.000001 Ordinary shares at par. In September 2024, the Company issued 233,332 £0.000001 Ordinary shares at par. In December 2024, the Company issued 36,284 £0.000001 Pre-Seed shares at a subscription price of £5.65 per share.
Page 5